386223-83-2
Chemical Structure
HN-1
- CAS No.: 386223-83-2
- Formula:C57H96N18O18
- Molecular Weight:1321.48
IUPAC Name: L-alanyl-L-prolyl-L-tryptophyl-L-histidyl-L-leucyl-L-seryl-L-seryl-L-glutaminyl-L-tyrosyl-L-seryl-L-arginyl-L-threonine
InChIKey: RFCMUGNTICGAAQ-HSVKAJNCSA-N
SMILES: O=C(N[C@@H](CO)C(N1[C@@H](CCC1)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC2=CNC=N2)C(N[C@@H](CC(N)=O)C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H]([C@H](O)C)N
Biological Activity: HN-1 is a tumor-specific internalizing peptide. HN-1 internalizes through receptor-mediated, energy-dependent, Clathrin-mediated endocytosis. HN-1 preferentially binds to invasive head and neck squamous cell carcinoma and is selectively internalized. HN-1 enhances the transfer of liposome-DNA complexes to head and neck squamous cell carcinoma. HN-1 can be used for research on head and neck squamous cell carcinoma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HN-1 | HN-1 is a tumor-specific internalizing peptide. HN-1 internalizes through receptor-mediated, energy-dependent, Clathrin-mediated endocytosis. HN-1 preferentially binds to invasive head and neck squamous cell carcinoma and is selectively internalized. HN-1 enhances the transfer of liposome-DNA complexes to head and neck squamous cell carcinoma. HN-1 can be used for research on head and neck squamous cell carcinoma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hong FD, et al. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res. 2000 Dec 1;60(23):6551-6. PMID: 11118031. [Content Brief]
- [2]. Hong FU, et al. Tumor specifically internalizing peptide 'HN-1': Targeting the putative receptor retinoblastoma-regulated discoidin domain receptor 1 involved in metastasis. World journal of clinical oncology. 2022 May 24;13(5):323-338.
- [3]. Wright CL, et al. Advancing theranostics with tumor-targeting peptides for precision otolaryngology. World journal of otorhinolaryngology - head and neck surgery. 2016 Jun;2(2):98-108.
